Piramal Pharma announced that the US FDA conducted a general GMP (Good Manufacturing Practices) Inspection of Piramal Pharma's facility at Aurora, Canada from 26 May 2025 to 30 May 2025.
The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation.